These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9539301)

  • 21. [Updated treatment of achondroplasia].
    Seino Y
    Clin Calcium; 2009 Mar; 19(3):432-6. PubMed ID: 19252254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
    Tauber M; Ester W; Auriol F; Molinas C; Fauvel J; Caliebe J; Nugent T; Fryklund L; Ranke MB; Savage MO; Clark AJ; Johnston LB; Hokken-Koelega AC;
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis.
    Miccoli M; Bertelloni S; Massart F
    Horm Res Paediatr; 2016; 86(1):27-34. PubMed ID: 27355624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GH and GnRH analog treatment in children who enter puberty at short stature.
    Tanaka T; Satoh M; Yasunaga T; Horikawa R; Tanae A; Hibi I
    J Pediatr Endocrinol Metab; 1997; 10(6):623-8. PubMed ID: 9467133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochodroplasia due to FGFR3 mutations.
    Alatzoglou KS; Hindmarsh PC; Brain C; Torpiano J; Dattani MT
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3959-63. PubMed ID: 19622626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone therapy in achondroplasia.
    Horton WA; Hecht JT; Hood OJ; Marshall RN; Moore WV; Hollowell JG
    Am J Med Genet; 1992 Mar; 42(5):667-70. PubMed ID: 1632435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
    Bellus GA; McIntosh I; Smith EA; Aylsworth AS; Kaitila I; Horton WA; Greenhaw GA; Hecht JT; Francomano CA
    Nat Genet; 1995 Jul; 10(3):357-9. PubMed ID: 7670477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone treatment for short stature in children born small for gestational age.
    Jung H; Rosilio M; Blum WF; Drop SL
    Adv Ther; 2008 Oct; 25(10):951-78. PubMed ID: 18836868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients.
    Carrascosa A; Esteban C; Espadero R; Fernández-Cancio M; Andaluz P; Clemente M; Audí L; Wollmann H; Fryklund L; Parodi L;
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3281-6. PubMed ID: 16804042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analyses from a centre of short- and long-term growth in Turner's syndrome on standard growth hormone doses confirm growth prediction algorithms and show normal IGF-I levels.
    Ranke MB; Schweizer R; Martin DD; Ehehalt S; Schwarze CP; Serra F; Binder G
    Horm Res Paediatr; 2012; 77(4):214-21. PubMed ID: 22433161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Final height in Turner syndrome patients treated with growth hormone.
    Pasquino AM; Passeri F; Municchi G; Segni M; Pucarelli I; Larizza D; Bossi G; Severi F; Galasso C
    Horm Res; 1996; 46(6):269-72. PubMed ID: 8982737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
    Noordam C; Peer PG; Francois I; De Schepper J; van den Burgt I; Otten BJ
    Eur J Endocrinol; 2008 Sep; 159(3):203-8. PubMed ID: 18562489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone therapy in hypochondroplasia.
    Ramaswami U; Hindmarsh PC; Brook CG
    Acta Paediatr Suppl; 1999 Feb; 88(428):116-7. PubMed ID: 10102069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G; Baur F; Schweizer R; Ranke MB
    J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular basis for the treatment of achondroplasia.
    Yamanaka Y; Ueda K; Seino Y; Tanaka H
    Horm Res; 2003; 60 Suppl 3():60-4. PubMed ID: 14671399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
    Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data.
    Tsai FJ; Tsai CH; Chang JG; Wu JY
    Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885
    [No Abstract]   [Full Text] [Related]  

  • 38. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
    Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG
    Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of growth hormone treatment in children with hypochondroplasia: comparison with an historical cohort.
    Pinto G; Cormier-Daire V; Le Merrer M; Samara-Boustani D; Baujat G; Fresneau L; Viaud M; Souberbielle JC; Pineau JC; Polak M
    Horm Res Paediatr; 2014; 82(6):355-63. PubMed ID: 25323764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between exon 3 polymorphism of growth hormone receptor gene and the responses to rhGH therapy.
    Wei Y; Zheng R; Zhou Y; Wang J; Bao P
    Int J Clin Exp Pathol; 2015; 8(6):7371-7. PubMed ID: 26261638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.